Literature DB >> 34328533

Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier.

Sung Hoon Kang1,2,3, Jeonghun Kim4, Jun Pyo Kim1,2, Soo Hyun Cho5, Yeong Sim Choe1,2,6, Hyemin Jang1,2, Hee Jin Kim1,2, Seong-Beom Koh3, Duk L Na1,2, Joon-Kyung Seong7,8,9, Sang Won Seo10,11,12,13,14.   

Abstract

PURPOSE: In this study, we used machine learning to develop a new method derived from a ligand-independent amyloid (Aβ) positron emission tomography (PET) classifier to harmonise different Aβ ligands.
METHODS: We obtained 107 paired 18F-florbetaben (FBB) and 18F-flutemetamol (FMM) PET images at the Samsung Medical Centre. To apply the method to FMM ligand, we transferred the previously developed FBB PET classifier to test similar features from the FMM PET images for application to FMM, which in turn developed a ligand-independent Aβ PET classifier. We explored the concordance rates of our classifier in detecting cortical and striatal Aβ positivity. We investigated the correlation of machine learning-based cortical tracer uptake (ML-CTU) values quantified by the classifier between FBB and FMM.
RESULTS: This classifier achieved high classification accuracy (area under the curve = 0.958) even with different Aβ PET ligands. In addition, the concordance rate of FBB and FMM using the classifier (87.5%) was good to excellent, which seemed to be higher than that in visual assessment (82.7%) and lower than that in standardised uptake value ratio cut-off categorisation (93.3%). FBB and FMM ML-CTU values were highly correlated with each other (R = 0.903).
CONCLUSION: Our findings suggested that our novel classifier may harmonise FBB and FMM ligands in the clinical setting which in turn facilitate the biomarker-guided diagnosis and trials of anti-Aβ treatment in the research field.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Aβ positivity; Concordance; Harmonisation; PET classifier

Mesh:

Substances:

Year:  2021        PMID: 34328533     DOI: 10.1007/s00259-021-05499-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  18 in total

1.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

Authors:  Henryk Barthel; Hermann-Josef Gertz; Stefan Dresel; Oliver Peters; Peter Bartenstein; Katharina Buerger; Florian Hiemeyer; Sabine M Wittemer-Rump; John Seibyl; Cornelia Reininger; Osama Sabri
Journal:  Lancet Neurol       Date:  2011-04-08       Impact factor: 44.182

2.  [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.

Authors:  Juha O Rinne; Dean F Wong; David A Wolk; Ville Leinonen; Steven E Arnold; Chris Buckley; Adrian Smith; Richard McLain; Paul F Sherwin; Gill Farrar; Marita Kailajärvi; Igor D Grachev
Journal:  Acta Neuropathol       Date:  2012-10-10       Impact factor: 17.088

3.  Amyloid involvement in subcortical regions predicts cognitive decline.

Authors:  Soo Hyun Cho; Jeong-Hyeon Shin; Hyemin Jang; Seongbeom Park; Hee Jin Kim; Si Eun Kim; Seung Joo Kim; Yeshin Kim; Jin San Lee; Duk L Na; Samuel N Lockhart; Gil D Rabinovici; Joon-Kyung Seong; Sang Won Seo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-06       Impact factor: 9.236

4.  Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions.

Authors:  Soo Hyun Cho; Yeong Sim Choe; Young Ju Kim; Hee Jin Kim; Hyemin Jang; Yeshin Kim; Si Eun Kim; Seung Joo Kim; Jun Pyo Kim; Young Hee Jung; Byeong C Kim; Samuel N Lockhart; Gill Farrar; Duk L Na; Seung Hwan Moon; Sang Won Seo
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

Review 6.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

7.  PET staging of amyloidosis using striatum.

Authors:  Bernard J Hanseeuw; Rebecca A Betensky; Elizabeth C Mormino; Aaron P Schultz; Jorge Sepulcre; John A Becker; Heidi I L Jacobs; Rachel F Buckley; Molly R LaPoint; Patrizia Vannini; Nancy J Donovan; Jasmeer P Chhatwal; Gad A Marshall; Kathryn V Papp; Rebecca E Amariglio; Dorene M Rentz; Reisa A Sperling; Keith A Johnson
Journal:  Alzheimers Dement       Date:  2018-05-21       Impact factor: 21.566

8.  Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.

Authors:  Milos D Ikonomovic; Chris J Buckley; Kerstin Heurling; Paul Sherwin; Paul A Jones; Michelle Zanette; Chester A Mathis; William E Klunk; Aruna Chakrabarty; James Ironside; Azzam Ismail; Colin Smith; Dietmar R Thal; Thomas G Beach; Gill Farrar; Adrian P L Smith
Journal:  Acta Neuropathol Commun       Date:  2016-12-12       Impact factor: 7.801

9.  Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes.

Authors:  Jun Pyo Kim; Jeonghun Kim; Yeshin Kim; Seung Hwan Moon; Yu Hyun Park; Sole Yoo; Hyemin Jang; Hee Jin Kim; Duk L Na; Sang Won Seo; Joon-Kyung Seong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.